
|Videos|August 13, 2021
Aurion Biotech: Treating endothelial disease with one donor
Author(s)David Hutton, Alex Delaney-Gesing
Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
Advertisement
Edward Holland, MD, chief medical advisor for Aurion Biotech, discusses the company's investigation of injectable endothelial cells, where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease as well as other forms of corneal edema.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA clears BVI’s FineVision HP trifocal IOL for the US market
2
Treating myopia today: US-focused treatments, challenges, and global insights
3
AAO 2025: A practice’s experience with connecting "the why," building community for techs
4
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
5